← Leaderboards
Charles Stiles
Dana-Farber Cancer Institute
$20,855,954
Attributed
$20,855,954
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$39,602,580 · 19
By mechanism
P01$25,306,857 · 10
T32$7,027,732 · 2
R01$5,241,608 · 2
P50$1,570,503 · 3
P30$300,887 · 1
R03$154,993 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- David H Rowitch$13,998,987
- William C Hahn$46,384,528
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorInhibitor/AntagonistSignal TransductionGliomaProgramsTranscription FactorBaseWomanSmall MoleculeDrug DevelopmentAstrocytomaNerve Stem CellMemberBrainPharmaceutical PreparationsResponseAdultMalignant GliomaMutantEpidermal Growth Factor ReceptorBrain NeoplasmsModalityStandard Of Care
Grant awards (92)
Program 30: Neuro-Oncology$73,710
P30 · FY2020 · CA · contact PI
Program 30: Neuro-Oncology$2,948
P30 · FY2020 · CA · contact PI
Program 30: Neuro-Oncology$72,080
P30 · FY2019 · CA · contact PI
Program 30: Neuro-Oncology$6,168
P30 · FY2019 · CA · contact PI
Program 30: Neuro-Oncology$75,340
P30 · FY2018 · CA · contact PI
Program 30: Neuro-Oncology$11,430
P30 · FY2018 · CA · contact PI
Program 30: Neuro-Oncology$5,848
P30 · FY2018 · CA · contact PI
Program 30: Neuro-Oncology$5,123
P30 · FY2018 · CA · contact PI
Program 30: Neuro-Oncology$3,833
P30 · FY2018 · CA · contact PI
Program 30: Neuro-Oncology$1,602
P30 · FY2018 · CA · contact PI
Targeting the OLIG2 Transcription Factor$316,873
P50 · FY2017 · CA · contact PI
Program 30: Neuro-Oncology$42,805
P30 · FY2017 · CA · contact PI
Targeting the OLIG2 Transcription Factor$303,630
P50 · FY2016 · CA · contact PI
OLIG2 Phosphorylation as a Drug Target for Glioma$436,292
R01 · FY2015 · NS · contact PI
Olig2 Antagonists for Targeted Therapy of Pediatric Astrocytomas$347,420
P01 · FY2015 · CA · contact PI
Targeting the OLIG2 Transcription Factor$303,108
P50 · FY2015 · CA · contact PI
OLIG2 Phosphorylation as a Drug Target for Glioma$431,962
R01 · FY2014 · NS · contact PI
Targeting the OLIG2 Transcription Factor$358,334
P50 · FY2014 · CA · contact PI
Olig2 Antagonists for Targeted Therapy of Pediatric Astrocytomas$340,394
P01 · FY2014 · CA · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01)$1,256,883
P01 · FY2013 · NS · contact PI
OLIG2 Phosphorylation as a Drug Target for Glioma$421,089
R01 · FY2013 · NS · contact PI
Olig2 Antagonists for Targeted Therapy of Pediatric Astrocytomas$317,459
P01 · FY2013 · CA · contact PI
Targeting the OLIG2 Transcription Factor$288,558
P50 · FY2013 · CA · contact PI
Oligl an(j demyelinating disease$272,163
P01 · FY2013 · NS · contact PI
Administration$74,441
P01 · FY2013 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01)$1,306,874
P01 · FY2012 · NS · contact PI
OLIG2 Phosphorylation as a Drug Target for Glioma$436,400
R01 · FY2012 · NS · contact PI
Olig2 Antagonists for Targeted Therapy of Pediatric Astrocytomas$391,728
P01 · FY2012 · CA · contact PI
Oligl an(j demyelinating disease$324,675
P01 · FY2012 · NS · contact PI
Administration$23,808
P01 · FY2012 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01)$1,314,080
P01 · FY2011 · NS · contact PI
OLIG2 Phosphorylation as a Drug Target for Glioma$432,675
R01 · FY2011 · NS · contact PI
Olig2 Antagonists for Targeted Therapy of Pediatric Astrocytomas$398,201
P01 · FY2011 · CA · contact PI
Oligl an(j demyelinating disease$325,510
P01 · FY2011 · NS · contact PI
Administration$23,896
P01 · FY2011 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01)$1,327,494
P01 · FY2010 · NS · contact PI
Tumor Cell Biology Training Program$480,882
T32 · FY2010 · CA · contact PI
Gene targets of OLIG2 in malignant glioma stem cells$423,225
R01 · FY2010 · NS · contact PI
Oligl an(j demyelinating disease$328,101
P01 · FY2010 · NS · contact PI
Administration$24,107
P01 · FY2010 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01)$1,310,745
P01 · FY2009 · NS · contact PI
Tumor Cell Biology Training Program$704,512
T32 · FY2009 · CA · contact PI
Gene targets of OLIG2 in malignant glioma stem cells$427,500
R01 · FY2009 · NS · contact PI
Oligl an(j demyelinating disease$321,847
P01 · FY2009 · NS · contact PI
Administration$23,623
P01 · FY2009 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells$1,351,294
P01 · FY2008 · NS · contact PI
Gene targets of OLIG2 in malignant glioma stem cells$427,500
R01 · FY2008 · NS · contact PI
Tumor Cell Biology Training Program$345,047
T32 · FY2008 · CA · contact PI
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$261,873
P01 · FY2008 · NS · contact PI
Core--Expression vector$89,360
P01 · FY2008 · NS · contact PI
Gene targets of OLIG2 in malignant glioma stem cells$85,500
R01 · FY2008 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells$1,385,359
P01 · FY2007 · NS · contact PI
Tumor Cell Biology Training Program$701,510
T32 · FY2007 · CA · contact PI
Gene targets of OLIG2 in malignant glioma stem cells$427,500
R01 · FY2007 · NS · contact PI
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$357,260
P01 · FY2007 · NS · contact PI
Core--Expression vector$121,901
P01 · FY2007 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells$1,398,357
P01 · FY2006 · NS · contact PI
Tumor Cell Biology Training Program$685,571
T32 · FY2006 · CA · contact PI
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$352,210
P01 · FY2006 · NS · contact PI
Signal Transduction in Myelinating Cells$317,265
R01 · FY2006 · NS · contact PI
Core--Expression vector$121,432
P01 · FY2006 · NS · contact PI
Molecular Mechanisms of Fate Choice in Neural Stem Cells$1,390,424
P01 · FY2005 · NS
Molecular Analysis of Neoplastic Disease$681,924
T32 · FY2005 · CA
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$341,950
P01 · FY2005 · NS
Signal Transduction in Myelinating Cells$324,900
R01 · FY2005 · NS
Core--Expression vector$117,896
P01 · FY2005 · NS
Molecular Mechanisms of Fate Choice in Neural Stem Cells$1,419,279
P01 · FY2004 · NS
Molecular Analysis of Neoplastic Disease$632,596
T32 · FY2004 · CA
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$331,991
P01 · FY2004 · NS
Signal Transduction in Myelinating Cells$324,900
R01 · FY2004 · NS
Core--Expression vector$114,461
P01 · FY2004 · NS
Small Molecule Kinase Inhibitor for Malignant Glioma$77,307
R03 · FY2004 · CA
MOLECULAR MECHANISMS OF FATE CHOICE IN NEURAL STEM CELLS$45,154
P01 · FY2004 · NS
SIGNAL TRANSDUCTION IN VERTEBRATE EMBRYO DEVELOPMENT$1,372,120
P01 · FY2003 · HD
Molecular Analysis of Neoplastic Disease$650,878
T32 · FY2003 · CA
Signal Transduction in Myelinating Cells$324,900
R01 · FY2003 · NS
Small Molecule Kinase Inhibitor for Malignant Glioma$77,686
R03 · FY2003 · CA
SIGNAL TRANSDUCTION IN VERTEBRATE EMBRYO DEVELOPMENT$1,337,758
P01 · FY2002 · HD
Molecular Analysis of Neoplastic Disease$662,032
T32 · FY2002 · CA
CORE-ADENOVIRUS$208,891
P01 · FY2002 · HD
IMMEDIATE EARLY GENES IN NEURAL FATE CHOICE$208,891
P01 · FY2002 · HD
MOLECULAR BIOLOGY OF ANIMAL CELL GROWTH FACTORS$144,397
T32 · FY2002 · CA
SIGNAL TRANSDUCTION IN VERTEBRATE EMBRYO DEVELOPMENT$1,304,405
P01 · FY2001 · HD
Molecular Analysis of Neoplastic Disease$608,684
T32 · FY2001 · CA
MOLECULAR BIOLOGY OF ANIMAL CELL GROWTH FACTORS$149,583
T32 · FY2001 · CA
CORE-ADENOVIRUS$0
P01 · FY2001 · HD
IMMEDIATE EARLY GENES IN NEURAL FATE CHOICE$0
P01 · FY2001 · HD
SIGNAL TRANSDUCTION IN VERTEBRATE EMBRYO DEVELOPMENT$1,271,554
P01 · FY2000 · HD
MOLECULAR ANALYSIS OF NEOPLASTIC DISEASE$401,332
T32 · FY2000 · CA
MOLECULAR BIOLOGY OF ANIMAL CELL GROWTH FACTORS$178,784
T32 · FY2000 · CA
CORE-ADENOVIRUS$174,795
P01 · FY2000 · HD
IMMEDIATE EARLY GENES IN NEURAL FATE CHOICE$174,793
P01 · FY2000 · HD